Login to Your Account



Financings Roundup

Calling Interference: Alnylam Stock Offering Garners $150M

By Randy Osborne
Staff Writer

Wednesday, January 16, 2013
Riding high after laying to rest its patent skirmish, Alnylam Pharmaceuticals Inc. priced its public offering of 8 million shares without a discount, selling them at Tuesday's closing price of $21.32, for net proceeds of about $151.1 million, or about $173.8 million if the underwriters exercise their full overallotment option of 1.2 million shares.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription